Breakthrough Infections during Phase 1 and 2 Prime-Boost HIV-1 Vaccine Trials with Canarypox Vectors (ALVAC) and Booster Dose of Recombinant gp120 or gp160

Candidate human immunodeficiency virus (HIV)-1 vaccines that elicit cytotoxic T lymphocytes may modulate HIV infection, requiring a prototype evaluation to assess participants who become infected with HIV. Of 1497 participants in canarypox HIV-1 vaccine prime-boost trials, 28 (1.9%) acquired HIV-1 i...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2004-09, Vol.190 (5), p.903-907
Main Authors: Lee, Deborah, Graham, Barney S., Chiu, Ya-Lin, Gilbert, Peter B., McElrath, M. Juliana, Belshe, Robert B., Buchbinder, Susan P., Sheppard, Haynes W., Koblin, Beryl A., Mayer, Kenneth H., Keefer, Michael C., Mulligan, Mark J., Celum, Connie L.
Format: Article
Language:English
Subjects:
AIDS vaccines
AIDS Vaccines - administration & dosage
AIDS Vaccines - immunology
Applied microbiology
Avipoxvirus - genetics
Biological and medical sciences
Blood plasma
Double-Blind Method
Experimentation
Female
Fundamental and applied biological sciences. Psychology
Genetic Vectors - administration & dosage
Genetic Vectors - genetics
Genetic Vectors - immunology
HIV
HIV 1
HIV Envelope Protein gp120 - administration & dosage
HIV Envelope Protein gp120 - genetics
HIV Envelope Protein gp120 - immunology
HIV Envelope Protein gp160 - administration & dosage
HIV Envelope Protein gp160 - genetics
HIV Envelope Protein gp160 - immunology
HIV Infections - physiopathology
HIV Infections - prevention & control
HIV-1 - pathogenicity
HIV/AIDS
Human immunodeficiency virus 1
Humans
Immunization
Immunization, Secondary
Infections
Infectious diseases
Male
Medical sciences
Microbiology
Miscellaneous
Placebos
Recombinant Proteins - administration & dosage
Recombinant Proteins - genetics
Recombinant Proteins - immunology
RNA, Viral - blood
T lymphocytes
Vaccination
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Virology
Viruses
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Candidate human immunodeficiency virus (HIV)-1 vaccines that elicit cytotoxic T lymphocytes may modulate HIV infection, requiring a prototype evaluation to assess participants who become infected with HIV. Of 1497 participants in canarypox HIV-1 vaccine prime-boost trials, 28 (1.9%) acquired HIV-1 infection after vaccination. Median plasma HIV-1 RNA levels (vaccinees, 4.78 log10 copies/mL; placebo recipients, 4.27 log10 copies/mL) and CD4 cell counts (vaccinees, 552 cells/mm3; placebo recipients, 657 cells/mm3) before administration of antiretroviral therapy (ART) and time to a composite end point (plasma HIV-1 RNA level >55,000 copies/mL, CD4 cell count
ISSN:0022-1899
1537-6613
DOI:10.1086/423284